Financial Statements/ESG Information - [Interim/Half-Year Report]

Immunotech Biopharm Ltd operates as a biopharmaceutical company. The Company develops and produces cellular immunotherapy products and other products. Immunotech Biopharm markets its products throughout China.

2024 Interim Report

Announcements and Notices - [Interim Results]

Announcement Of The Interim Results
For The Six Months Ended 30 June 2024

Announcements and Notices - [Date of Board Meeting]

Date Of Board Meeting

Announcements and Notices - [Change in Company Secretary]

Resignation Of Chief Financial Officer,
Company Secretary And Authorised Representative
And
Appointment Of Joint Company Secretaries And
Authorised Representative And
Waiver From Strict Compliance
With Rules 3.28 And 8.17 Of The Listing Rules

Announcements and Notices - [Discloseable Transaction]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Immunotech Biopharm (6978 HK)

2024 Interim Report

Announcement Of The Interim Results For The Six Months Ended 30 June 2024

Date Of Board Meeting

Resignation Of Chief Financial Officer, Company Secretary And Authorised Representative And Appointment Of Joint Company Secretaries And Authorised Representative And Waiver From Strict Compliance With Rules 3.28 And 8.17 Of The Listing Rules

Discloseable Transaction Disposal Of The Certificates Of Deposits

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)